DGIdb - PILOCARPINE Drug Record

PILOCARPINE chembl:CHEMBL550 Approved

Alternate Names:

PILOCARPINE
OCUSERT PILO
OCUSERT PILO-20
OCUSERT PILO-40
(3S,4R)-3-ETHYLDIHYDRO-4-((1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-2(3H)-FURANONE
(3S-CIS)-3-ETHYLDIHYDRO-4-[(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-2(3H)-FURANONE
SALAGEN®
PILOCARPINE HYDROCHLORIDE
PILOCARPINE NITRATE
(+)-PILOCARPINE
PILOKARPIN
drugbank:01085
rxcui:8328
pubchem.compound:5910
chembl:CHEMBL550
chemidplus:92-13-7

Drug Info:

Year of Approval	approved before 1982
Drug Class	miotics
Drug Class	anti-glaucomic agents
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	for treatment of incontinence
Drug Groups	investigational
Drug Categories	antiglaucoma preparations and miotics
Drug Categories	cholinergic receptor agonist
Drug Categories	cytochrome p-450 cyp2a6 inhibitors (strong)
Drug Categories	cytochrome p-450 cyp3a4 inhibitors
Drug Categories	cytochrome p-450 cyp3a4 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 enzyme inhibitors
Drug Categories	ophthalmologicals
Drug Categories	parasympathomemetic (cholinergic) agents
Drug Categories	sensory organs

(6 More Sources)

Publications:

Lindholm et al., 1994, Brain-derived neurotrophic factor and neurotrophin-4 increase neurotrophin-3 expression in the rat hippocampus., Int. J. Dev. Neurosci.
Ekström, 1977, Choline acetyltransferase activity in parotid glands of rats after prolonged treatment with pilocarpine., Acta Physiol. Scand.
Poulsen et al., 2004, Differential expression of brain-derived neurotrophic factor transcripts after pilocarpine-induced seizure-like activity is related to mode of Ca2+ entry., Neuroscience
Figueroa et al., 2009, Selectivity of agonists for the active state of M1 to M4 muscarinic receptor subtypes., J. Pharmacol. Exp. Ther.
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Chen X et al., 2015, Rational design of partial agonists for the muscarinic m1 acetylcholine receptor., J Med Chem
Sykes et al., 2009, Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor., Mol. Pharmacol.
Moreno-Vinasco et al., 2009, Retinoic acid prevents virus-induced airway hyperreactivity and M2 receptor dysfunction via anti-inflammatory and antiviral effects., Am. J. Physiol. Lung Cell Mol. Physiol.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Hall et al., 1984, Serotonin and acetylcholine affect the release of prolactin and growth hormone from pituitary glands of domestic fowl in vitro in the presence of hypothalamic tissue., Acta Endocrinol.
Clinckers et al., 2005, Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepine: concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity., J. Pharmacol. Exp. Ther.
Bucci et al., Effects of age on pilocarpine-induced c-fos expression in rat hippocampus and cortex., Neurobiol. Aging
Pitarque M et al., 2001, Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity., Biochem Biophys Res Commun
Malaiyandi V et al., 2006, Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy., Mol Psychiatry
Gambier N et al., 2005, Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort., Pharmacogenomics J
Nakajima M et al., 2006, Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations., Clin Pharmacol Ther
di Iulio J et al., 2009, In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function., Pharmacogenet Genomics
Endo T et al., 2008, Genetic polymorphisms of CYP2A6 affect the in-vivo pharmacokinetics of pilocarpine., Pharmacogenet Genomics
Nurfadhlina M et al., 2006, CYP2A6 polymorphisms in Malays, Chinese and Indians., Xenobiotica
Oscarson M et al., 1999, Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism., FEBS Lett
Gyamfi MA et al., 2005, High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana., Eur J Clin Pharmacol
Elens L et al., 2010, Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients., Pharmacogenomics
Tan W et al., 2001, Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population., Int J Cancer
Schoedel KA et al., 2004, Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians., Pharmacogenetics
Kaida Y et al., 2008, The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer., Clin Pharmacol Ther
Tan L et al., 2010, The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients., Clin Neurol Neurosurg
Zhang X et al., 2001, Lack of association between smoking and CYP2A6 gene polymorphisms in A Japanese population., Nihon Arukoru Yakubutsu Igakkai Zasshi
Ishii Y et al., 2010, Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?, Cancer Chemother Pharmacol
Kimura M et al., 2005, Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans., Drug Metab Dispos
Ariyoshi N et al., 2001, A novel single nucleotide polymorphism altering stability and activity of CYP2a6., Biochem Biophys Res Commun
Murai K et al., 2009, Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes., Xenobiotica
Rao Y et al., 2000, Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking., Mol Pharmacol
Djordjevic N et al., 2010, In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population., Eur J Clin Pharmacol
Huang S et al., 2005, CYP2A6, MAOA, DBH, DRD4, and 5HT2A genotypes, smoking behaviour and cotinine levels in 1518 UK adolescents., Pharmacogenet Genomics
Audrain-McGovern J et al., 2007, The role of CYP2A6 in the emergence of nicotine dependence in adolescents., Pediatrics
Daigo S et al., 2002, A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur., Pharmacogenetics
Fukami T et al., 2005, Characterization of novel CYP2A6 polymorphic alleles (CYP2A618 and CYP2A619) that affect enzymatic activity., Drug Metab Dispos
Tanii H et al., 2011, Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women., Eur J Clin Pharmacol
Kitagawa K et al., 1999, The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP., Biochem Biophys Res Commun
Hirose T et al., 2010, Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer., Oncol Rep
Ariyoshi N et al., 2002, Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers., Cancer Epidemiol Biomarkers Prev
Yoshida R et al., 2003, Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro., Clin Pharmacol Ther
Kong SY et al., 2009, Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer., Pharmacogenomics
Yamanaka H et al., 2004, Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted., Eur J Pharm Sci
Fujieda M et al., 2004, Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers., Carcinogenesis
Wang H et al., 2011, Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes., Pharmacogenomics
Minematsu N et al., 2006, Limitation of cigarette consumption by CYP2A64, 7 and *9 polymorphisms., Eur Respir J
Arab-Alameddine M et al., 2009, Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals., Clin Pharmacol Ther
Xu C et al., 2002, An in vivo pilot study characterizing the new CYP2A67, 8, and *10 alleles., Biochem Biophys Res Commun
Ando M et al., 2003, Association of CYP2A6 gene deletion with cigarette smoking status in Japanese adults., J Epidemiol
Endo T et al., 2007, Involvement of CYP2A6 in the formation of a novel metabolite, 3-hydroxypilocarpine, from pilocarpine in human liver microsomes., Drug Metab Dispos
Fujita K et al., 2008, CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1., Cancer Sci
Iwahashi K et al., 2004, Whole deletion of CYP2A6 gene (CYP2A6AST;4C) and smoking behavior., Neuropsychobiology
Peamkrasatam S et al., 2006, In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais., Drug Metab Pharmacokinet
Benowitz NL et al., 2006, CYP2A6 genotype and the metabolism and disposition kinetics of nicotine., Clin Pharmacol Ther
French et al., 1999, Hippocampal neurotrophin and trk receptor mRNA levels are altered by local administration of nicotine, carbachol and pilocarpine., Brain Res. Mol. Brain Res.

PILOCARPINE CYP2A6

Interaction Score: 6.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11394901 16402128 15940289 16952495 19238117 18698229 16891249 10544257 15660270 20860463 11241319 15475735 18212800 20089352 11725533 19921195 15980104 11237731 19845430 10999944 20155256 16272956 17130279 12042667 15900015 21494765 10448083 20596643 12223434 12844137 19604090 15265511 15308589 21521021 16452582 19225447 11779172 12749606 17178767 18380793 14981342 17220563 17112802

Sources:
PharmGKB
PILOCARPINE FOS

Interaction Score: 0.74

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9661997

Sources:
NCI
PILOCARPINE CHAT

Interaction Score: 0.74

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
842358

Sources:
NCI
PILOCARPINE NTF3

Interaction Score: 0.51

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7747601

Sources:
NCI
PILOCARPINE CHRM1

Interaction Score: 0.27

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Partial agonist

PMIDs:
18824613 17139284 17016423 25478907

Sources:
TEND DTC TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions
PILOCARPINE PRL

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
6144226

Sources:
NCI
PILOCARPINE CHRM2

Interaction Score: 0.24

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Novel drug target Established target

Trial Name THVD-201

Specific Action of the Ligand Partial agonist

PMIDs:
18824613 19465517 11752352

Sources:
TEND TdgClinicalTrial DrugBank GuideToPharmacology
PILOCARPINE CHRM3

Interaction Score: 0.18

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Novel drug target Established target

Trial Name THVD-201

Specific Action of the Ligand Partial agonist

PMIDs:
18824613 19498041

Sources:
TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions
PILOCARPINE NTRK2

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15183516

Sources:
NCI
PILOCARPINE ABCC1

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15860570

Sources:
NCI
PILOCARPINE CHRM4

Interaction Score: 0.15

Interaction Types & Directionality:

partial agonist (activating)

agonist (activating)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Partial agonist

PMIDs:
18824613

Sources:
DrugBank GuideToPharmacology
PILOCARPINE NTRK1

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10101239

Sources:
NCI
PILOCARPINE BDNF

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15183516

Sources:
NCI
PILOCARPINE CHRM5

Interaction Score: 0.1

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Partial agonist

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
TTD GuideToPharmacology

DrugBank: DB01085

Version: 5.1.7

Alternate Names:

Pilocarpine 6% Drug Brand

92-13-7 CAS Number

ACAT SUK Kit (Accelerated COVID-19 Antibody Test Single Use Kit) Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

Figueroa et al., 2009, Selectivity of agonists for the active state of M1 to M4 muscarinic receptor subtypes., J. Pharmacol. Exp. Ther.

Moreno-Vinasco et al., 2009, Retinoic acid prevents virus-induced airway hyperreactivity and M2 receptor dysfunction via anti-inflammatory and antiviral effects., Am. J. Physiol. Lung Cell Mol. Physiol.

Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.

TdgClinicalTrial: PILOCARPINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications for treatment of incontinence

Drug Class Small Molecule

FDA Approval approved

Publications:
TEND: PILOCARPINE
- Version: 01-August-2011
Alternate Names:

Drug Info:

Drug Class anti-glaucomic agents

Drug Class miotics

Year of Approval approved before 1982

Publications:

NCI: PILOCARPINE

Version: 14-September-2017

Alternate Names:

C748 NCI drug code

Drug Info:

Publications:

Poulsen et al., 2004, Differential expression of brain-derived neurotrophic factor transcripts after pilocarpine-induced seizure-like activity is related to mode of Ca2+ entry., Neuroscience

French et al., 1999, Hippocampal neurotrophin and trk receptor mRNA levels are altered by local administration of nicotine, carbachol and pilocarpine., Brain Res. Mol. Brain Res.

Lindholm et al., 1994, Brain-derived neurotrophic factor and neurotrophin-4 increase neurotrophin-3 expression in the rat hippocampus., Int. J. Dev. Neurosci.

DTC: PILOCARPINE
- Version: 02-September-2020
Alternate Names:

CHEMBL550 ChEMBL Drug ID

Drug Info:

Publications:

Chen X et al., 2015, Rational design of partial agonists for the muscarinic m1 acetylcholine receptor., J Med Chem

PharmGKB: pilocarpine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Pitarque M et al., 2001, Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity., Biochem Biophys Res Commun

Malaiyandi V et al., 2006, Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy., Mol Psychiatry

Gambier N et al., 2005, Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort., Pharmacogenomics J

TTD: Pilocarpine
- Version: 2020.06.01
Alternate Names:

D06HLY TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL550
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL550
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
GuideToPharmacology: 135650824
- Version: 29-September-2020
Alternate Names:

Drug Info:

Publications:

Direct Interaction?	False
Endogenous Drug?	False
Specific Action of the Ligand	Partial agonist

Novel drug target	Established target
Trial Name	THVD-201
Specific Action of the Ligand	Partial agonist

Pilocarpine 6%	Drug Brand
92-13-7	CAS Number
ACAT SUK Kit (Accelerated COVID-19 Antibody Test Single Use Kit)	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Groups	investigational

PILOCARPINE Drug Record

PILOCARPINE chembl:CHEMBL550 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9661997

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 842358

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 7747601

Sources: NCI

Interaction Types & Directionality: agonist (activating)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Partial agonist

PMIDs: 18824613 17139284 17016423 25478907

Sources: TEND DTC TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 6144226

Sources: NCI

Interaction Types & Directionality: agonist (activating)

Interaction Info: Novel drug target Established target Trial Name THVD-201 Specific Action of the Ligand Partial agonist

PMIDs: 18824613 19465517 11752352

Sources: TEND TdgClinicalTrial DrugBank GuideToPharmacology

Interaction Types & Directionality: agonist (activating)

Interaction Info: Novel drug target Established target Trial Name THVD-201 Specific Action of the Ligand Partial agonist

PMIDs: 18824613 19498041

Sources: TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15183516

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15860570

Sources: NCI

Interaction Types & Directionality: partial agonist (activating) agonist (activating)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Partial agonist

PMIDs: 18824613

Sources: DrugBank GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10101239

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15183516

Sources: NCI

Interaction Types & Directionality: agonist (activating)

Interaction Info: Specific Action of the Ligand Partial agonist Endogenous Drug? False Direct Interaction? False

PMIDs: None found

Sources: TTD GuideToPharmacology

DrugBank: DB01085

Alternate Names: Pilocarpine 6% Drug Brand 92-13-7 CAS Number ACAT SUK Kit (Accelerated COVID-19 Antibody Test Single Use Kit) Drug Brand

Drug Info: Drug Type small molecule Drug Groups approved Drug Groups investigational

TdgClinicalTrial: PILOCARPINE

Alternate Names:

Drug Info: Drug Indications for treatment of incontinence Drug Class Small Molecule FDA Approval approved

Publications:

TEND: PILOCARPINE

Alternate Names:

Drug Info: Drug Class anti-glaucomic agents Drug Class miotics Year of Approval approved before 1982

Publications:

NCI: PILOCARPINE

Alternate Names: C748 NCI drug code

Drug Info:

DTC: PILOCARPINE

Alternate Names: CHEMBL550 ChEMBL Drug ID

Drug Info:

Publications: Chen X et al., 2015, Rational design of partial agonists for the muscarinic m1 acetylcholine receptor., J Med Chem

PharmGKB: pilocarpine

Alternate Names:

Interaction Types & Directionality:

n/a

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
9661997

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
842358

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
7747601

Sources:
NCI

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Partial agonist

PMIDs:
18824613 17139284 17016423 25478907

Sources:
TEND DTC TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
6144226

Sources:
NCI

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Novel drug target Established target

Trial Name THVD-201

Specific Action of the Ligand Partial agonist

PMIDs:
18824613 19465517 11752352

Sources:
TEND TdgClinicalTrial DrugBank GuideToPharmacology

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Novel drug target Established target

Trial Name THVD-201

Specific Action of the Ligand Partial agonist

PMIDs:
18824613 19498041

Sources:
TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
15183516

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15860570

Sources:
NCI

Interaction Types & Directionality:

partial agonist (activating)

agonist (activating)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Partial agonist

PMIDs:
18824613

Sources:
DrugBank GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
10101239

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15183516

Sources:
NCI

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Partial agonist

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
TTD GuideToPharmacology

Alternate Names:

Pilocarpine 6% Drug Brand

92-13-7 CAS Number

ACAT SUK Kit (Accelerated COVID-19 Antibody Test Single Use Kit) Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Drug Info:

Drug Indications for treatment of incontinence

Drug Class Small Molecule

FDA Approval approved

Drug Info:

Drug Class anti-glaucomic agents

Drug Class miotics

Year of Approval approved before 1982

Alternate Names:

C748 NCI drug code

Alternate Names:

CHEMBL550 ChEMBL Drug ID

Publications:

Chen X et al., 2015, Rational design of partial agonists for the muscarinic m1 acetylcholine receptor., J Med Chem

Alternate Names:

D06HLY TTD Drug ID